Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Lifesci Capital

Lifesci Capital began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report sent to investors on Monday, Marketbeat reports. The firm issued an outperform rating and a $41.00 price objective on the stock.

Several other equities research analysts have also issued reports on the stock. TD Cowen initiated coverage on shares of Oruka Therapeutics in a research report on Monday. They set a buy rating for the company. Wedbush initiated coverage on Oruka Therapeutics in a research note on Wednesday, September 4th. They set an outperform rating and a $40.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a buy rating and a $40.00 price objective on the stock. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of Buy and an average target price of $41.25.

Oruka Therapeutics Trading Down 4.1 %

Shares of NASDAQ:ORKA opened at $25.38 on Monday. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.